Voltage-gated sodium channel NaV1 family (NaV1) (NaV1)

The Voltage-gated sodium channel NaV1 family (NaV1) consists of nine alpha-subunit isoforms (NaV1.1 through NaV1.9) that are fundamental to the electrical excitability of neurons, cardiomyocytes, and skeletal muscle cells (Catterall, 2012). These channels are large, complex transmembrane proteins that open rapidly in response to membrane depolarization, allowing an influx of sodium ions that triggers the rising phase of the action potential (IUPHAR/BPS, 2023). Each isoform exhibits distinct tissue distribution and physiological roles; for instance, NaV1.1, NaV1.2, and NaV1.6 are primary in the central nervous system, while NaV1.5 is the predominant cardiac isoform (de Lera Ruiz & Kraus, 2015). Mutations in the genes encoding these channels (SCN1A–SCN11A) are associated with a variety of channelopathies, including severe forms of epilepsy, life-threatening cardiac arrhythmias like Brugada syndrome, and chronic pain conditions such as erythromelalgia (StatPearls, 2023). Pharmacologically, the NaV1 family is a major target for several classes of drugs, including local anesthetics, antiarrhythmics, and anticonvulsants, which typically act by blocking the aqueous pore or stabilizing the inactivated state of the channel (Catterall, 2012). While traditional agents often lack isoform selectivity, leading to side effects like dizziness or cardiac conduction issues, modern drug development is focused on creating highly selective inhibitors (PubMed, 2021). Specifically, targeting peripheral isoforms like NaV1.7, NaV1.8, and NaV1.9 is a major strategy for developing non-opioid analgesics that avoid the central and cardiac toxicities associated with broader NaV1 inhibition (Nature Reviews Drug Discovery, 2020).

Other names

Voltage-gated sodium channelsVGSCsSodium channel alpha subunitsSCN family

Drugs targeting the NaV1 family primarily act as pore blockers or gating modifiers that bind to the alpha subunit, inhibiting sodium ion influx and preventing membrane depolarization, which effectively suppresses the firing of action potentials in overactive or hypersensitive tissues (Catterall, 2012; IUPHAR/BPS, 2023).